JP2023520929A5 - - Google Patents

Info

Publication number
JP2023520929A5
JP2023520929A5 JP2022561484A JP2022561484A JP2023520929A5 JP 2023520929 A5 JP2023520929 A5 JP 2023520929A5 JP 2022561484 A JP2022561484 A JP 2022561484A JP 2022561484 A JP2022561484 A JP 2022561484A JP 2023520929 A5 JP2023520929 A5 JP 2023520929A5
Authority
JP
Japan
Prior art keywords
composition according
optionally
cov
sars
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022561484A
Other languages
English (en)
Japanese (ja)
Other versions
JP7840570B2 (ja
JP2023520929A (ja
Filing date
Publication date
Priority claimed from US16/875,487 external-priority patent/US11116737B1/en
Application filed filed Critical
Priority claimed from PCT/US2021/026588 external-priority patent/WO2021207606A1/en
Publication of JP2023520929A publication Critical patent/JP2023520929A/ja
Publication of JP2023520929A5 publication Critical patent/JP2023520929A5/ja
Application granted granted Critical
Publication of JP7840570B2 publication Critical patent/JP7840570B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022561484A 2020-04-10 2021-04-09 コロナウイルス感染症の処置のための方法 Active JP7840570B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202063008624P 2020-04-10 2020-04-10
US63/008,624 2020-04-10
US202063023021P 2020-05-11 2020-05-11
US63/023,021 2020-05-11
US16/875,487 2020-05-15
US16/875,487 US11116737B1 (en) 2020-04-10 2020-05-15 Methods of using probenecid for treatment of coronavirus infections
EP20202059.0 2020-10-15
EP20202059.0A EP3892269B1 (en) 2020-04-10 2020-10-15 Probenecid for treating coronavirus infections
US202163151551P 2021-02-19 2021-02-19
US63/151,551 2021-02-19
PCT/US2021/026588 WO2021207606A1 (en) 2020-04-10 2021-04-09 Methods for treatment of coronavirus infections

Publications (3)

Publication Number Publication Date
JP2023520929A JP2023520929A (ja) 2023-05-22
JP2023520929A5 true JP2023520929A5 (enExample) 2024-04-16
JP7840570B2 JP7840570B2 (ja) 2026-04-06

Family

ID=78023981

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022561484A Active JP7840570B2 (ja) 2020-04-10 2021-04-09 コロナウイルス感染症の処置のための方法

Country Status (5)

Country Link
EP (1) EP4132503B1 (enExample)
JP (1) JP7840570B2 (enExample)
CN (1) CN116075298B (enExample)
AU (1) AU2021254262A1 (enExample)
WO (1) WO2021207606A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4157288A2 (en) * 2020-06-02 2023-04-05 Institut Gustave-Roussy Modulators of purinergic receptors and related immune checkpoint for treating acute respiratory distress syndrom
CA3224519A1 (en) * 2021-07-06 2023-01-12 Ralph A. Tripp Compositions and methods for treating and preventing viral infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005005596A2 (en) * 2003-06-18 2005-01-20 Chinese National Human Genome Center At Shanghai Characterization of the earliest stages of the severe acute respiratory syndrome (sars) virus and uses thereof
MX341050B (es) * 2010-04-07 2016-08-05 Celgene Corp * Metodos para tratar infeccion viral respiratoria.
US20130280806A1 (en) * 2010-05-17 2013-10-24 Donald Rubin Mammalian genes involved in infection
US11554112B2 (en) * 2018-06-07 2023-01-17 Herum Therapeutics International Limited Combinations of β-lactam compounds and probenecid and uses thereof
MY205435A (en) * 2018-09-14 2024-10-21 Jiangyin Usun Pharmaceutical Co Ltd New conjugates of montelukast and peptides
BR112021024310A2 (pt) * 2019-06-05 2022-02-15 Univ Emory Peptidomiméticos para o tratamento de infecções por coronavírus e picornavírus

Similar Documents

Publication Publication Date Title
JP2024170583A5 (enExample)
JP2023535744A5 (enExample)
US20230201497A1 (en) Method for pulsatile delivery of a gaseous drug
JP2023520323A5 (enExample)
JP2023520929A5 (enExample)
US20220387455A1 (en) Treatment of moderate to severe influenza
CN111658779A (zh) 治疗新型冠状病毒肺炎的联合用药物
JP2024504225A5 (enExample)
JP2023520591A5 (enExample)
JP2022553888A5 (enExample)
JP2022019937A (ja) ヒト又は動物の慢性若しくは急性のウイルス感染症及び／又は敗血症の予防若しくは治療のための組成物
FI4199922T3 (fi) (1r,3s)-3-((5-syano-4-fenyylitiatsol-2-yyli)karbamoyyli)syklopentaani-1-karboksyylihappo käytettäväksi hengitystietautien hoidossa
JP2023537369A5 (enExample)
JP2023520703A5 (enExample)
JP2024543259A5 (enExample)
JP2024531799A5 (enExample)
CN115884770A (zh) 治疗冠状病毒感染的联用药物及治疗方法
CN115867288A (zh) 用于治疗呼吸系统病症的组合物
Van Wyk The common cold and influenza: colds & flu
US12171732B2 (en) Compositions and use of N-chlorotaurine for treatment and prevention of respiratory infections
KR20220009314A (ko) 사스-코로나바이러스-2 감염증 예방 또는 치료용 약학 조성물
TW202606651A (zh) 用於預防或治療認知功能不全的苯甲酸鹽
AR124436A1 (es) Formulación de polvo seco de muteína de lipocalina para el tratamiento del asma
CN116531491A (zh) 一种干扰素α1b在制备防治甲型流感病毒感染引发的疾病的药物中的用途
BR102020005172A2 (pt) Zinco como medicamento antiviral eficaz para a família coronaviridae e seus genomas, gêneros e grupos